Novartis touts more late-stage data for inclisiran, the once-centerpiece heart drug spurned by the FDA
Novartis bet large on The Medicines Company’s RNAi heart drug inclisiran, expecting to shake up that segment of the market with a swift US approval. But after getting stiff-armed by the FDA last year, the pharma giant’s now releasing more post-hoc data in the hopes of finally running it past the goal line.
Patients who took inclisiran — or Leqvio, as it’s marketed in the EU — in three Phase III trials saw sustained reductions in bad cholesterol of about 50% compared to placebo at month 17, regardless of body mass index, Novartis announced at this year’s American Heart Association virtual conference.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,500+ biopharma pros reading Endpoints daily — and it's free.